Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Felzartamab in IgA Nephropathy
NCT07889362Phase 2Not yet recruiting
- Sponsor
- Biogen
- Start
- Nov 2026
- Primary completion
- Aug 2028
01
Overview
A Phase 2 trial of felzartamab in immunoglobulin A nephropathy (IgAN), sponsored by Biogen. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
felzartamab
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07889362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07889362.